Web Stats Provided By Google Analytics

The Raw Stem Cell News Feed

The Stem Cell Research Newswire: Comprehensive Real-Time News Feed for Stem Cell Research

Monday, June 24, 2013

Aegis Capital Initiates Neostem at Buy on Stem Cell Platforms

In a report published Monday, Aegis Capital analyst Raghuram Selvaraju initiated coverage on Neostem with a Buy rating and $2.50 price target.

http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3699477/update-aegis-capital-initiates-neostem-at-buy-on-stem-ce

No comments:

Post a Comment

Popular Stem Cell Roundup Posts